Zhejiang Wecome Pharmaceutical announced that the company achieved a revenue of 0.297 billion yuan in the first half of 2024, a decrease of 6.15% compared to the same period last year; the net income attributable to shareholders of the listed company was 14.1921 million yuan, a decrease of 78.04%.
维康药业：2024年上半年净利润同比下降78.04%
Zhejiang Wecome Pharmaceutical: net income in the first half of 2024 decreased by 78.04% compared to the same period last year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated